Henan Yangsen Pharmaceutical Group Co., Ltd. agreed to acquire an additional 51% stake in Shanghai Modern Hasen (Shangqiu) Pharmaceutical Co., Ltd. from Shanghai Shyndec Pharmaceutical Co., Ltd. (SHSE:600420) for approximately CNY 110 million on October 18, 2025. Henan Yangsen Pharmaceutical Group Co., Ltd. paid a deposit of CNY 32.9 million to the Shanghai United Equity Exchange, which will be directly transferred to the purchase price of this Equity Transaction upon the effectiveness of this Contract. One-time payment. In addition to the deposit directly transferred to the purchase price of this Equity Transaction as mentioned in the preceding paragraph, and will pay the remaining purchase price of CNY 76.78 in one lump sum to the designated bank account of the Shanghai United Equity Exchange within five business days of the date of signing this Contract.

For the period ending December 31, 2024, Shanghai Modern Hasen (Shangqiu) Pharmaceutical Co., Ltd. reported total revenue of CNY 366.29 million. As of December 31, 2024, Shanghai Modern Hasen (Shangqiu) Pharmaceutical Co., Ltd. reported total assets of CNY 406.09 million and total common equity of CNY 171.93 million.

Henan Yangsen Pharmaceutical Group Co., Ltd. completed the acquisition of an additional 51% stake in Shanghai Modern Hasen (Shangqiu) Pharmaceutical Co., Ltd. from Shanghai Shyndec Pharmaceutical Co., Ltd. (SHSE:600420) on October 30, 2025.